These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 16625243)

  • 1. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
    Santel A; Aleku M; Keil O; Endruschat J; Esche V; Fisch G; Dames S; Löffler K; Fechtner M; Arnold W; Giese K; Klippel A; Kaufmann J
    Gene Ther; 2006 Aug; 13(16):1222-34. PubMed ID: 16625243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
    Santel A; Aleku M; Keil O; Endruschat J; Esche V; Durieux B; Löffler K; Fechtner M; Röhl T; Fisch G; Dames S; Arnold W; Giese K; Klippel A; Kaufmann J
    Gene Ther; 2006 Sep; 13(18):1360-70. PubMed ID: 16625242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.
    Urban-Klein B; Werth S; Abuharbeid S; Czubayko F; Aigner A
    Gene Ther; 2005 Mar; 12(5):461-6. PubMed ID: 15616603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.
    Spagnou S; Miller AD; Keller M
    Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes.
    Werth S; Urban-Klein B; Dai L; Höbel S; Grzelinski M; Bakowsky U; Czubayko F; Aigner A
    J Control Release; 2006 May; 112(2):257-70. PubMed ID: 16574264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted lipoplexes for siRNA delivery.
    Cardoso A; Trabulo S; Moreira JN; Düzgüneş N; de Lima MC
    Methods Enzymol; 2009; 465():267-87. PubMed ID: 19913172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convenient targeting of stealth siRNA-lipoplexes to cells with chelator lipid-anchored molecules.
    Herringson TP; Altin JG
    J Control Release; 2009 Nov; 139(3):229-38. PubMed ID: 19595724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
    Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
    Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A
    J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
    Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
    Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gene-silencing effect of siRNA in cationic lipoplexes is enhanced by incorporating pDNA in the complex.
    Tagami T; Barichello JM; Kikuchi H; Ishida T; Kiwada H
    Int J Pharm; 2007 Mar; 333(1-2):62-9. PubMed ID: 17097247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels.
    Hassani Z; Lemkine GF; Erbacher P; Palmier K; Alfama G; Giovannangeli C; Behr JP; Demeneix BA
    J Gene Med; 2005 Feb; 7(2):198-207. PubMed ID: 15515135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer.
    Yano J; Hirabayashi K; Nakagawa S; Yamaguchi T; Nogawa M; Kashimori I; Naito H; Kitagawa H; Ishiyama K; Ohgi T; Irimura T
    Clin Cancer Res; 2004 Nov; 10(22):7721-6. PubMed ID: 15570006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
    Golzio M; Mazzolini L; Ledoux A; Paganin A; Izard M; Hellaudais L; Bieth A; Pillaire MJ; Cazaux C; Hoffmann JS; Couderc B; Teissié J
    Gene Ther; 2007 May; 14(9):752-9. PubMed ID: 17344906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1.
    Shen J; Samul R; Silva RL; Akiyama H; Liu H; Saishin Y; Hackett SF; Zinnen S; Kossen K; Fosnaugh K; Vargeese C; Gomez A; Bouhana K; Aitchison R; Pavco P; Campochiaro PA
    Gene Ther; 2006 Feb; 13(3):225-34. PubMed ID: 16195704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
    Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
    Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. siRNA delivery in vivo.
    Sioud M
    Methods Mol Biol; 2005; 309():237-49. PubMed ID: 15990404
    [No Abstract]   [Full Text] [Related]  

  • 19. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma.
    Guo B; Zhang Y; Luo G; Li L; Zhang J
    Anat Rec (Hoboken); 2009 May; 292(5):633-9. PubMed ID: 19382240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.